SKSachiko Kamikawa

Sachiko Kamikawa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sachiko Kamikawa has a total of 2 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Effects of Everolimus on Tacrolimus-Accelerated Progression of Renal Interstitial Fibrosis in Subtotal Nephrectomized Rats

    by Yuko Nakayama, Sachiko Kamikawa, Satohiro Masuda

    Chronic kidney disease (CKD) is characterized by progressive glomerulosclerosis and interstitial fibrosis, ultimately leading to irreversible renal dysfunction. Tacrolimus, a calcineurin inhibitor widely used after kidney transplantation, is known to accelerate chronic renal injury, whereas everolimus has been introduced as a calcineurin inhibitor–sparing agent. However, their direct effects on renal fibrogenesis remain incompletely defined. In this study, we established a chronic renal failure model using 5/6 nephrectomized rats to evaluate tacrolimus-accelerated renal interstitial fibrosis and the impact of concomitant everolimus treatment. Low-dose tacrolimus (1 mg/kg every other day) administered for two weeks starting four weeks after nephrectomy markedly accelerated interstitial fibrotic progression, accompanied by histological deterioration and increased albuminuria. Co-administration of low-dose everolimus (1 mg/kg every other day) significantly attenuated tacrolimus-accelerated fibrosis and improved functional and structural renal parameters. Histological analyses demonstrated reduced interstitial fibrosis and glomerular alterations in the everolimus-treated group. Although α-smooth muscle actin expression was not significantly suppressed, everolimus restored autophagic activity, as indicated by normalization of the LC3-II/LC3-I ratio in both in vivo and in vitro experiments. These findings indicate that tacrolimus accelerates renal fibrogenesis in a remnant kidney model and that concomitant low-dose everolimus effectively mitigates this progression, providing a time- and cost-efficient experimental platform for evaluating antifibrotic strategies in CKD.